Copyright Reports & Markets. All rights reserved.

Global Drugs of Bioengineered Protein Key Trends and Opportunities to 2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Drugs of Bioengineered Protein Market Size by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Monoclonal Antibodies
    • 1.2.3 Therapeutic Proteins
    • 1.2.4 Vaccines
  • 1.3 Market by Application
    • 1.3.1 Global Drugs of Bioengineered Protein Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Endocrinology
    • 1.3.3 Immunology
    • 1.3.4 Hematology
    • 1.3.5 Infectiology
    • 1.3.6 Neurology
    • 1.3.7 Oncology
    • 1.3.8 Genetic Disorder
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trend

  • 2.1 Global Drugs of Bioengineered Protein Market Perspective (2016-2027)
  • 2.2 Global Drugs of Bioengineered Protein Growth Trends by Regions
    • 2.2.1 Drugs of Bioengineered Protein Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Drugs of Bioengineered Protein Historic Market Size by Regions (2016-2021)
    • 2.2.3 Drugs of Bioengineered Protein Forecasted Market Size by Regions (2022-2027)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Drugs of Bioengineered Protein Industry Trends
    • 2.3.2 Drugs of Bioengineered Protein Market Drivers
    • 2.3.3 Drugs of Bioengineered Protein Market Challenges
    • 2.3.4 Drugs of Bioengineered Protein Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Drugs of Bioengineered Protein Players by Market Size
    • 3.1.1 Players Covered: Ranking by Drugs of Bioengineered Protein Revenue
    • 3.1.2 Global Top Drugs of Bioengineered Protein Players by Revenue (2016-2021)
    • 3.1.3 Global Drugs of Bioengineered Protein Revenue Market Share by Players (2016-2021)
    • 3.1.4 Global Drugs of Bioengineered Protein Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Drugs of Bioengineered Protein Market Concentration Ratio
    • 3.2.1 Global Drugs of Bioengineered Protein Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 5 and Top 10 Players by Drugs of Bioengineered Protein Revenue in 2020
  • 3.3 Drugs of Bioengineered Protein Key Players Head office and Area Served
  • 3.4 Key Players Drugs of Bioengineered Protein Product Solution and Service
  • 3.5 Date of Enter into Drugs of Bioengineered Protein Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Global Drugs of Bioengineered Protein Breakdown Data by Type (2016-2027)

  • 4.1 Global Drugs of Bioengineered Protein Historic Market Size by Type (2016-2021)
  • 4.2 Global Drugs of Bioengineered Protein Forecasted Market Size by Type (2022-2027)

5 Global Drugs of Bioengineered Protein Breakdown Data by Application (2016-2027)

  • 5.1 Global Drugs of Bioengineered Protein Historic Market Size by Application (2016-2021)
  • 5.2 Drugs of Bioengineered Protein Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Drugs of Bioengineered Protein Market Size (2016-2027)
  • 6.2 Key Drugs of Bioengineered Protein Players Market Share in North America (2020-2021)
  • 6.3 North America Drugs of Bioengineered Protein Market Size by Country
    • 6.3.1 North America Drugs of Bioengineered Protein Sales by Country (2016-2021)
    • 6.3.2 North America Drugs of Bioengineered Protein Market Size Forecast by Country (2022-2027)
  • 6.4 U.S. Market Size Analysis
    • 6.4.1 U.S. Drugs of Bioengineered Protein Market Size (2016-2027)
    • 6.4.2 U.S. Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 6.4.3 U.S. Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 6.5 Canada Market Size Analysis
    • 6.5.1 Canada Drugs of Bioengineered Protein Market Size (2016-2027)
    • 6.5.2 Canada Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 6.5.3 Canada Drugs of Bioengineered Protein Market Size by Application (2016-2027)

7 Europe

  • 7.1 Europe Drugs of Bioengineered Protein Market Size (2016-2027)
  • 7.2 Key Drugs of Bioengineered Protein Players Market Share in Europe (2020-2021)
  • 7.3 Europe Drugs of Bioengineered Protein Market Size by Country
    • 7.3.1 Europe Drugs of Bioengineered Protein Sales by Country (2016-2021)
    • 7.3.2 Europe Drugs of Bioengineered Protein Market Size Forecast by Country (2022-2027)
  • 7.4 Germany Market Size Analysis
    • 7.4.1 Germany Drugs of Bioengineered Protein Market Size (2016-2027)
    • 7.4.2 Germany Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 7.4.3 Germany Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 7.5 France Market Size Analysis
    • 7.5.1 France Drugs of Bioengineered Protein Market Size (2016-2027)
    • 7.5.2 France Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 7.5.3 France Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 7.6 U.K. Market Size Analysis
    • 7.6.1 U.K. Drugs of Bioengineered Protein Market Size (2016-2027)
    • 7.6.2 U.K. Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 7.6.3 U.K. Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 7.7 Italy Market Size Analysis
    • 7.7.1 Italy Drugs of Bioengineered Protein Market Size (2016-2027)
    • 7.7.2 Italy Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 7.7.3 Italy Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 7.8 Russia Market Size Analysis
    • 7.8.1 Russia Drugs of Bioengineered Protein Market Size (2016-2027)
    • 7.8.2 Russia Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 7.8.3 Russia Drugs of Bioengineered Protein Market Size by Application (2016-2027)

8 Asia-Pacific

  • 8.1 Asia-Pacific Drugs of Bioengineered Protein Market Size (2016-2027)
  • 8.2 Key Drugs of Bioengineered Protein Players Market Share in Asia-Pacific (2020-2021)
  • 8.3 Asia-Pacific Drugs of Bioengineered Protein Market Size by Region
    • 8.3.1 Asia-Pacific Drugs of Bioengineered Protein Sales by Region (2016-2021)
    • 8.3.2 Asia-Pacific Drugs of Bioengineered Protein Market Size Forecast by Region (2022-2027)
  • 8.4 China Market Size Analysis
    • 8.4.1 China Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.4.2 China Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.4.3 China Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.5 Japan Market Size Analysis
    • 8.5.1 Japan Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.5.2 Japan Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.5.3 Japan Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.6 South Korea Market Size Analysis
    • 8.6.1 South Korea Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.6.2 South Korea Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.6.3 South Korea Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.7 India Market Size Analysis
    • 8.7.1 India Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.7.2 India Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.7.3 India Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.8 Australia Market Size Analysis
    • 8.8.1 Australia Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.8.2 Australia Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.8.3 Australia Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.9 Taiwan Market Size Analysis
    • 8.9.1 Taiwan Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.9.2 Taiwan Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.9.3 Taiwan Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.10 Indonesia Market Size Analysis
    • 8.10.1 Indonesia Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.10.2 Indonesia Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.10.3 Indonesia Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.11 Thailand Market Size Analysis
    • 8.11.1 Thailand Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.11.2 Thailand Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.11.3 Thailand Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.12 Malaysia Market Size Analysis
    • 8.12.1 Malaysia Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.12.2 Malaysia Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.12.3 Malaysia Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.13 Philippines Market Size Analysis
    • 8.13.1 Philippines Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.13.2 Philippines Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.13.3 Philippines Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 8.14 Vietnam Market Size Analysis
    • 8.14.1 Vietnam Drugs of Bioengineered Protein Market Size (2016-2027)
    • 8.14.2 Vietnam Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 8.14.3 Vietnam Drugs of Bioengineered Protein Market Size by Application (2016-2027)

9 Latin America

  • 9.1 Latin America Drugs of Bioengineered Protein Market Size (2016-2027)
  • 9.2 Key Drugs of Bioengineered Protein Players Market Share in Latin America (2020-2021)
  • 9.3 Latin America Drugs of Bioengineered Protein Market Size by Country
    • 9.3.1 Latin America Drugs of Bioengineered Protein Sales by Country (2016-2021)
    • 9.3.2 Latin America Drugs of Bioengineered Protein Market Size Forecast by Country (2022-2027)
  • 9.4 Mexico Market Size Analysis
    • 9.4.1 Mexico Drugs of Bioengineered Protein Market Size (2016-2027)
    • 9.4.2 Mexico Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 9.4.3 Mexico Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 9.5 Brazil Market Size Analysis
    • 9.5.1 Brazil Drugs of Bioengineered Protein Market Size (2016-2027)
    • 9.5.2 Brazil Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 9.5.3 Brazil Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 9.6 Argentina Market Size Analysis
    • 9.6.1 Argentina Drugs of Bioengineered Protein Market Size (2016-2027)
    • 9.6.2 Argentina Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 9.6.3 Argentina Drugs of Bioengineered Protein Market Size by Application (2016-2027)

10 Middle East & Africa

  • 10.1 Middle East & Africa Drugs of Bioengineered Protein Market Size (2016-2027)
  • 10.2 Key Drugs of Bioengineered Protein Players Market Share in Middle East & Africa (2020-2021)
  • 10.3 Middle East & Africa Drugs of Bioengineered Protein Market Size by Country
    • 10.3.1 Middle East & Africa Drugs of Bioengineered Protein Sales by Country (2016-2021)
    • 10.3.2 Middle East & Africa Drugs of Bioengineered Protein Market Size Forecast by Country (2022-2027)
  • 10.4 Turkey Market Size Analysis
    • 10.4.1 Turkey Drugs of Bioengineered Protein Market Size (2016-2027)
    • 10.4.2 Turkey Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 10.4.3 Turkey Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 10.5 Saudi Arabia Market Size Analysis
    • 10.5.1 Saudi Arabia Drugs of Bioengineered Protein Market Size (2016-2027)
    • 10.5.2 Saudi Arabia Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 10.5.3 Saudi Arabia Drugs of Bioengineered Protein Market Size by Application (2016-2027)
  • 10.6 UAE Market Size Analysis
    • 10.6.1 UAE Drugs of Bioengineered Protein Market Size (2016-2027)
    • 10.6.2 UAE Drugs of Bioengineered Protein Market Size by Type (2016-2027)
    • 10.6.3 UAE Drugs of Bioengineered Protein Market Size by Application (2016-2027)

11 Key Players Profiles

  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Company Details
    • 11.1.2 GlaxoSmithKline Business Overview and Its Total Revenue
    • 11.1.3 GlaxoSmithKline Drugs of Bioengineered Protein Introduction
    • 11.1.4 GlaxoSmithKline Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.1.5 GlaxoSmithKline Recent Development
  • 11.2 Johnson & Johnson
    • 11.2.1 Johnson & Johnson Company Details
    • 11.2.2 Johnson & Johnson Business Overview and Its Total Revenue
    • 11.2.3 Johnson & Johnson Drugs of Bioengineered Protein Introduction
    • 11.2.4 Johnson & Johnson Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.2.5 Johnson & Johnson Recent Development
  • 11.3 Merck
    • 11.3.1 Merck Company Details
    • 11.3.2 Merck Business Overview and Its Total Revenue
    • 11.3.3 Merck Drugs of Bioengineered Protein Introduction
    • 11.3.4 Merck Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.3.5 Merck Recent Development
  • 11.4 Novartis
    • 11.4.1 Novartis Company Details
    • 11.4.2 Novartis Business Overview and Its Total Revenue
    • 11.4.3 Novartis Drugs of Bioengineered Protein Introduction
    • 11.4.4 Novartis Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.4.5 Novartis Recent Development
  • 11.5 Sanofi
    • 11.5.1 Sanofi Company Details
    • 11.5.2 Sanofi Business Overview and Its Total Revenue
    • 11.5.3 Sanofi Drugs of Bioengineered Protein Introduction
    • 11.5.4 Sanofi Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.5.5 Sanofi Recent Development
  • 11.6 Eli Lilly
    • 11.6.1 Eli Lilly Company Details
    • 11.6.2 Eli Lilly Business Overview and Its Total Revenue
    • 11.6.3 Eli Lilly Drugs of Bioengineered Protein Introduction
    • 11.6.4 Eli Lilly Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.6.5 Eli Lilly Recent Development
  • 11.7 Roche
    • 11.7.1 Roche Company Details
    • 11.7.2 Roche Business Overview and Its Total Revenue
    • 11.7.3 Roche Drugs of Bioengineered Protein Introduction
    • 11.7.4 Roche Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.7.5 Roche Recent Development
  • 11.8 Dr. Reddy's Laboratories
    • 11.8.1 Dr. Reddy's Laboratories Company Details
    • 11.8.2 Dr. Reddy's Laboratories Business Overview and Its Total Revenue
    • 11.8.3 Dr. Reddy's Laboratories Drugs of Bioengineered Protein Introduction
    • 11.8.4 Dr. Reddy's Laboratories Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.8.5 Dr. Reddy's Laboratories Recent Development
  • 11.9 Abbott Laboratories
    • 11.9.1 Abbott Laboratories Company Details
    • 11.9.2 Abbott Laboratories Business Overview and Its Total Revenue
    • 11.9.3 Abbott Laboratories Drugs of Bioengineered Protein Introduction
    • 11.9.4 Abbott Laboratories Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.9.5 Abbott Laboratories Recent Development
  • 11.10 Amgen
    • 11.10.1 Amgen Company Details
    • 11.10.2 Amgen Business Overview and Its Total Revenue
    • 11.10.3 Amgen Drugs of Bioengineered Protein Introduction
    • 11.10.4 Amgen Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.10.5 Amgen Recent Development
  • 11.11 Bayer AG
    • 11.11.1 Bayer AG Company Details
    • 11.11.2 Bayer AG Business Overview and Its Total Revenue
    • 11.11.3 Bayer AG Drugs of Bioengineered Protein Introduction
    • 11.11.4 Bayer AG Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.11.5 Bayer AG Recent Development
  • 11.12 Biocon
    • 11.12.1 Biocon Company Details
    • 11.12.2 Biocon Business Overview and Its Total Revenue
    • 11.12.3 Biocon Drugs of Bioengineered Protein Introduction
    • 11.12.4 Biocon Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.12.5 Biocon Recent Development
  • 11.13 Fresenius kabi
    • 11.13.1 Fresenius kabi Company Details
    • 11.13.2 Fresenius kabi Business Overview and Its Total Revenue
    • 11.13.3 Fresenius kabi Drugs of Bioengineered Protein Introduction
    • 11.13.4 Fresenius kabi Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.13.5 Fresenius kabi Recent Development
  • 11.14 Panacea Biotec
    • 11.14.1 Panacea Biotec Company Details
    • 11.14.2 Panacea Biotec Business Overview and Its Total Revenue
    • 11.14.3 Panacea Biotec Drugs of Bioengineered Protein Introduction
    • 11.14.4 Panacea Biotec Revenue in Drugs of Bioengineered Protein Business (2016-2021)
    • 11.14.5 Panacea Biotec Recent Development

12 Analyst's Viewpoints/Conclusion

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source

    Drugs of Bioengineered Protein market is segmented by companies, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs of Bioengineered Protein market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on market size and forecast for the period 2016-2027.
    Segment by Type, the Drugs of Bioengineered Protein market is segmented into Monoclonal Antibodies, Therapeutic Proteins, Vaccines, etc.
    Segment by Application, the Drugs of Bioengineered Protein market is segmented into Endocrinology, Immunology, Hematology, Infectiology, Neurology, Oncology, Genetic Disorder, etc.

    Regional and Country-level Analysis
    The report offers exhaustive assessment of different region-wise and country-wise Drugs of Bioengineered Protein markets such as the U.S., Canada, Germany, France, the U.K., Italy, Russia, China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Argentina, Saudi Arabia, UAE, Turkey, etc.
    The report includes country-wise and region-wise market size for the period 2016-2027, by countries (regions), by Type, and by Application, as well as by players for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

    Competitive Landscape and Drugs of Bioengineered Protein Market Share Analysis
    Drugs of Bioengineered Protein market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2016-2021. Details included are company description, major business, company total revenue and revenue generated in Drugs of Bioengineered Protein business, the date to enter into the Drugs of Bioengineered Protein market, Drugs of Bioengineered Protein product introduction, recent developments, etc.
    The major vendors include GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Sanofi, Eli Lilly, Roche, Dr. Reddy's Laboratories, Abbott Laboratories, Amgen, Bayer AG, Biocon, Fresenius kabi, Panacea Biotec, etc.

    Buy now